SciClone Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported total net revenue of USD 38,991,000 compared to USD 37,946,000 a year ago. Income from operations was USD 5,953,000 compared to loss from operations of USD 4,857,000 a year ago. Income before provision for income tax was USD 5,967,000 compared to loss before benefit for income tax of USD 4,568,000 a year ago. Net income was USD 6,338,000 or USD 0.12 per diluted share compared to net loss of USD 4,022,000 or USD 0.08 per basic and diluted share a year ago. Non-GAAP net income USD 10,688,000 or USD 0.20 per diluted share compared to USD 13,548,000 or USD 0.26 per diluted share a year ago.

For the six months, the company reported total net revenue of USD 75,490,000 compared to USD 71,514,000 a year ago. Income from operations was USD 15,377,000 compared to USD 4,626,000 a year ago. Income before provision for income tax was USD 15,778,000 compared to USD 4,964,000 a year ago. Net income USD 14,202,000 or USD 0.27 per diluted share compared to USD 4,940,000 or USD 0.09 per diluted share a year ago. Non-GAAP net income USD 20,392,000 or USD 0.39 per diluted share compared to USD 23,316,000 or USD 0.44 per diluted share a year ago.

For the year 2016, the company expects revenue to be in the range of USD 158 million to USD 163 million and expects that non-GAAP earnings per share on a fully diluted basis to be in the range of USD 0.70 to USD 0.74 for the year.